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Background: Lassa hemorrhagic fever (LHF) is a rodent-borne viral disease that can be fatal for human beings.
In this study, an attenuated Lassa vaccine candidate, ML29, was tested in SIV-infected rhesus macaques for its
ability to elicit immune responses without instigating signs pathognomonic for arenavirus disease. ML29 is a
reassortant between Lassa and Mopeia viruses that causes a transient infection in non-human primates and
confers sterilizing protection from lethal Lassa viral challenge. However, since the LHF endemic area of West
Africa also has high HIV seroprevalence, it is important to determine whether vaccination could be safe in the
context of HIV infection.
Results: SIV-infected and uninfected rhesus macaques were vaccinated with the ML29 virus and monitored for
specific humoral and cellular immune responses, as well as for classical and non-classical signs of arenavirus
disease. Classical disease signs included viremia, rash, respiratory distress, malaise, high liver enzyme levels, and
virus invasion of the central nervous system. Non-classical signs, derived from profiling the blood transcriptome
of virulent and non-virulent arenavirus infections, included increased expression of interferon-stimulated genes
(ISG) and decreased expression of COX2, IL-1β, coagulation intermediates and nuclear receptors needed for
stress signaling. All vaccinated monkeys showed ML29-specific antibody responses and ML29-specific cell-
mediated immunity.
Conclusion: SIV-infected and uninfected rhesus macaques responded similarly to ML29 vaccination, and none
developed chronic arenavirus infection. Importantly, none of the macaques developed signs, classical or non-
classical, of arenavirus disease.
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Lassa hemorrhagic fever (LHF) is a rodent-transmitted
disease that causes more than 300,000 human cases per
year in the West African endemic area. Mortality rates
are between 15-20% in hospitalized individuals, and
reach 50% in epidemic episodes [1,2]. Those who de-
velop effective antiviral immunity survive, while those
with uncontrolled high viral loads succumb [3-5]. Lassa
virus (LASV) replicates in almost all human tissues with
the highest titers being found in liver and secondary
lymphoid organs. However, the extent of tissue damage
is not enough to implicate the failure of any one organ
as the cause of death [1,6]. Besides viremia, other signs
of LHF include myocarditis, pulmonary edema, and in
advanced cases, hemorrhage and hypovolemic shock
resulting from vascular leakage [6]. Due to the undiffer-
entiated symptoms at the onset of LHF, the opportunity
to administer ribavirin treatment is often missed; so the
best public health option in endemic areas would be
vaccination.
Many LHF vaccines have shown promise in small ani-
mal models: viral sub-particles, peptides, DNA vaccines
and viral vectors [7]. The most effective candidates have
been attenuated vectors that protected against LASV
challenge in primate models: vaccinia virus expressing
LASV glycoprotein (GP) and nucleocapsid protein (NP)
[8], vesicular stomatitis virus expressing LASV GP [9],
and the ML29 reassortant vaccine expressing the GP
and NP of LASV and the Z and L proteins of Mopeia
virus (MOPV) [10-13]. A yellow fever vaccine, YF17D,
expressing LASV GP (YF-LASV-GP) was protective in
guinea pigs [14] but not in primates (ISL unpublished).
ML29 is the only Lassa vaccine candidate that elicited
strong cell-mediated immunity before challenge and that
provided sterilizing immunity in several animal models
[7,10-13]. For all the live attenuated vectors, safety con-
cerns remain to be addressed before launching clinical
trials.
One safety concern is that the Lassa endemic region of
West Africa has high seroprevalence for infection with
Human Immunodeficiency Virus-1 (HIV): 5-12% of
young adults are HIV positive [15] with most of these
individuals being unaware that they are HIV-infected.
Several vaccine studies have attempted to model vaccin-
ation of HIV-infected individuals by delivering attenu-
ated vaccines to immune-deficient animals: a Rift Valley
Fever vaccine was given to immune-deficient mice [16],
an Ebola vaccine (VSV-EBOGP) was given to SHIV-
infected monkeys [17], and a smallpox vaccine was given
to SIV-infected monkeys [18]. Two of these studies
selected viremic monkeys with low CD4 counts. Mon-
keys for our study had been infected with a pathogenic
stock of SIVmac251, and vaccinated with VSVgag that
doubles the ordinarily one-year lifespans of SIV-infectedmacaques [19], thereby prolonging the time available for
the study.
The Mopeia/Lassa (ML29) reassortant virus used in
this study can be an effective, broadly cross-reactive
Lassa vaccine [7,11,20,21]. The large (L) genomic seg-
ment of ML29 is derived from the mild MOPV [22-25].
The S segment of ML29 encodes the NP and GP gene
products derived from LASV [10-13,26,27]. ML29
appears to be even more attenuated than its parental
MOPV both in vitro and in vivo [10,11].
In this study, we employed SIV-infected macaques as a
model for persons living with HIV. Our goal was to de-
termine whether ML29 is safe and immunogenic in
macaques during advanced stages of SIV-infection.
Results
Rhesus macaque survival and viral loads
The experimental plan is diagrammed in Figure 1. Briefly,
393 days after infection with SIVmac251, eleven rhesus
macaques were enrolled in this study. Eight macaques were
inoculated with an attenuated LASV vaccine ML-29, in
order to determine whether they could still elicit LASV-
specific immune responses without developing signs of
arenavirus disease. Five of the 8 were given ML29 subcuta-
neously (s.c.) and 3 were given ML29 intragastrically (i.g.).
Both routes were successful, but the i.g. route required a
higher dose [28]. Three additional SIV-infected macaques
were inoculated with LCMV-Armstrong known from
previous studies to cause a brief, uneventful infection in
SIV-infected monkeys (MSS and JCZ unpublished). As
controls, 5 healthy non-SIV-infected rhesus macaques were
vaccinated s.c. with ML29.
SIV-positive animals were classified as slow, median or
rapid progressors based on their physical signs and SIV
viral loads at set point, i.e. 3 months after infection
(Table 1, Figure 2A, B, and C). Seven of the 8 SIV/ML29
monkeys experienced a drop in SIV titers (median 20%)
during the first week after ML29 inoculation, but those
titers returned the following week (Figure 2D).
Two rapid-progressors were euthanized on days 34
and 63 and two median progressors were euthanized on
days 57 and 105 after ML29 vaccination (Table 1,
Figures 2 and 3). The first euthanized animal (SIV/ML-
3) had high SIV loads and wasted appearance prior to
ML29 vaccination. This animal developed a barely-
detectable ML29 viremia (103 pfu/ml of plasma) 3 weeks
after vaccination. (This titer of 103 pfu ML29/ml is still
below the >104 pfu/ml considered to be a disease sign
related to poor prognosis in LHF). Transient ML29
viremia (80 pfu/ml of plasma) was also detected one
week after vaccination in the second euthanized monkey
(SIV/ML-1), and in a long-term surviving monkey (SIV/
ML-8 had 20 pfu/ml plasma) 3 weeks after vaccination
(Figure 4).
Figure 1 Experimental design. Sixteen rhesus macaques were inoculated with SIVmac251 and monitored for viral loads and SIV-specific
immunity. Five succumbed within a year after SIV inoculation (48, 222, 223, 231, and 240 days after SIV infection) and the remaining 11 monkeys
were vaccinated with ML29 or LCMV-Armstrong on day 393 after SIV-infection. A month after the vaccination, five monkeys (ML-1, SIV/ML-1, SIV/
ML-2, SIV/ML-6, SIV/ML-7) were boosted with ML29. Necropsies for 6 animals were performed on days 426, 452, 458, 491, 505, and 516 (after SIV).
Five months after ML29 vaccination, 5 animals were still surviving. (X) indicates the relative position on the timeline of samplings and necropsies.
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plaque assay in 3 of 8 SIV-infected monkeys but not in
non-SIV-infected monkeys (Table 1). When ML29 was
not detectable by direct plaque assay or by RT-PCR, it
could sometimes be detected by a 2-step amplification
in which plasma or "infected" cells were co-cultured with
Vero cells, then the media was harvested and subjected
to conventional plaque assay. By this sensitive assay,
ML29 was detected in plasma of 2 of 5 non-SIV-infected
monkeys (ML-3 at week 1 and ML4-at week 2 after
ML29 vaccination). Solid tissues of ML29-vaccinated
monkeys (spleen, LN, brain, liver, kidney, heart, lung,
adrenals) were all negative for ML29 by direct plaque
assays.
Urine samples were collected from the monkeys
weekly and assessed for virus shedding. Only two of the
monkeys (SIV/ML-7 and SIV/ML-6) had detectable
virus in urine during weeks two and three after ML29
inoculation respectively. The shed virus was not ML29
by plaque morphology or by detection arrays [29] which
showed it to be Adenovirus 52, a virus that has been iso-
lated previously from zookeepers [30,31] and can cause
subclinical infection in non-human primates [32].
Rationale for euthanizing animals in these studies
All four of the earliest-euthanized SIV-infected animals
had wasting that began prior to ML29-inoculation. Upon
necropsy it was evident they also had swollen ileo-caecal
lymph nodes that are a hallmark of terminal AIDS [33].
Five of the original 16 SIV-infected monkeys died of
AIDS prior to the onset of the ML29 vaccinations, and
the time to death of the 11 remaining monkeys was not
detectably influenced by the ML29 vaccination. Twomajor signs of virulent arenavirus disease and more spe-
cifically of lethal Lassa fever are high levels of liver
enzymes and petechiae [6]. None of the ML29-vaccinated
animals in this study showed high liver enzyme levels. All
hematological and chemical parameters [urine analysis
(BUN, creatinine), blood chemistry (glucose, cholesterol),
blood cell counts, hematocrit, and erythrocyte sedimenta-
tion] were within normal ranges and no macaques devel-
oped clinical manifestations of arenavirus disease. This
absence of arenavirus-specific pathology resembles previ-
ous ML29 trials in monkeys, marmosets and guinea pigs
[10,12,13].
At the end of this study, approximately 5 months after
the first ML29 vaccination, 5 animals (SIV/ML-2, SIV/
ML-4, SIVML-5, SIV/ML-8, SIV/ARM-2) were still
healthy, never having shown signs of arenavirus disease.
ML29-specific humoral and cellular immune responses
In previous work we reported that rhesus macaques
infected with the lethal LCMV-WE and non-pathogenic
LCMV-Armstrong showed a drop in circulating NK and
γδT cells, indicating that this is not a disease-specific
event but instead infection-associated lymphopenia [34].
In agreement with this work, the analysis of blood cell
subsets, in both SIV-infected and non-infected controls,
showed a decrease in percentage of circulating NK
(CD16+) cells a week after vaccination (Figure 5A and B).
The CD14+ (monocyte) population showed a modest in-
crease in the SIV-infected group and a marked increase in
the control group one week after ML29 vaccination
(Figure 5C and D).
Anti-LASV IgG antibodies were detected by ELISA
from weeks 1 to week 5 and then monthly until the time
Table 1 Immune responses and viremia in SIV/ML29-infected monkeys and controls
Animal ID Cell-mediated immunity









at set point f
SIV/ML-1 sca ++++ ++++ 80 pfu/ml Week 8 (M) 105-106
SIV/ML-2 sc ++ ++++ —— >20 wks (S) 103-104
SIV/ML-3 sc ++ +++ 1000 pfu/ml Week 4 (R) 107-108
SIV/ML-4 sc ++ ++++ —— >20 wks (M) 105-106
SIV/ML-5 sc +++ +++ —— >20 wks (S) 104-105
SIV/ML-6 ig +++++ —— —— Week 14 (M) 105-106
SIV/ML-7 ig —— —— —— Week 19 (M) 105
SIV/ML-8 ig +++ —— 20 pfu/ml >20 wks (M) 105-106
SIV/ARM-1 sc ++ ++ —— Week 16 (R) 107
SIV/ARM-2 sc ++ ++++ —— >20 wks (S) 104
SIV/ARM-3 sc +++ +++ —— Week 9 (R) 106-107
ML-1 sc +++ ++++ —— >20 wks ——
ML-2 sc +++ +++ —— >20 wks ——
ML-3 sc ++ +++ + >20 wks ——
ML-4 sc +++ +++ + >20 wks ——
ML-5 sc ++ +++ —— >20 wks ——
a SIV/ML-1 to SIV/ML-5 are macaques that were SIV-infected, then 393 days later, they were ML29-infected via a subcutaneous (sc) route. SIV/ML-6 to 8 were
similarly SIV-infected, but then vaccinated with ML29 by an intragastric (ig) route. SIV/ARM-1 to 3 were SIV-infected and inoculated over a year later with LCMV-
Armstrong by the subcutaneous route. Monkeys ML-1 through ML-5 were never SIV-infected and were all inoculated sc with ML29 only.
b IFNγ responses for 8 SIV/ML animals, SIV/ARM animals and 5 ML29-vaccinated animals were followed up to 22 weeks. Primary arenavirus-specific responses were
measured by IFNγ intracellular staining: maximum staining (+++++) corresponds to 0.4% of CD8+ cells, and minimum staining (+) corresponds to 0.012%. Since
staining was negligible for CD4+ lymphocytes, measurements are only shown for CD8+ lymphocytes. (− − −) means non-detectable.
c Arenavirus-specific antibody responses were measured by ELISA. The minimum and maximum optical density readings at 450 nm were 1.2 and 2.9 at 1:100
dilution, respectively. OD higher than 0.5 was considered positive.
d Viremia in plasma of 3 ML29-vaccinated animals refers to the transient presence of infectious ML29 particles detected by conventional plaque assay. By sensitive
2-step co-cultivation assays, none of the other SIV-infected animals had detectable ML29 in plasma or urine. (+) in two non-SIV-infected monkeys means the
plasma of these animals had co-cultivation-detectable ML29 in plasma (week 1 for ML-3 and week 2 for ML-4).
e Time of euthanasia for those animals that lost more that 10% of body weight.
f SIV viral loads. Animals were classified as Rapid AIDS progressors (R) with >106 viral particles/ml; Medium, (M) between 105-106 viral particles/ml; and Slow (S)
with <105 viral particles/ml.
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IgG except for those 3 given ML29 by the i.g. route. Op-
tical densities (OD450) were observed to be higher than
1.25 for a 1:100 plasma dilution, when compared with
negative controls at 0.30 OD450 (Table 1).
Cell-mediated immunity is believed to mediate LASV
clearance from blood and tissues of immunized animals.
Previously, we showed that a single s.c. ML29 im-
munization of rhesus macaques induced robust cell-
mediated immune responses detectable in peripheral
blood as early as 7 days after immunization [10]. Here
the ML29-specific immune responses were measured by
intracellular staining flow cytometry (ICS) for gamma-
interferon (IFNγ) and confirmed by IFNγ ELISpot. High
cell mediated immunity (++++) means that 0.4% of CD8+
T cells stained with intracellular IFNγ or that ELISpot
levels exceded 200 positive cells per 106. Low cell
mediated immunity (+) means that 0.012% of CD8+ T
cells stained with intracellular IFNγ or that ELISpot levelswere less than 100 positive cells per 106. All 5 control ani-
mals and seven of the 8 SIV-infected vaccinees had vigor-
ous ML29-specific cell-mediated immunity by the first
week after vaccination (Table 1). The animal with no
ML29-specific cell-mediated response, (SIV/ML-7), also
failed to produce anti-LASV IgG antibodies and survived
19 weeks after ML29 vaccination. When SIV/ML-7 finally
succumbed, at a time consistent with median progression,
it displayed the swollen ileo-caecal lymph nodes and
increased SIV titer associated with AIDS [33]. Neither the
ML-29 vaccine virus nor arenavirus disease symptoms
were detected in SIV/ML-7. For those animals that sur-
vived longer than 16 weeks after ML29 vaccination,
vaccine-specific cell-mediated immune responses lasted at
least 18 weeks. The study was not designed to compare
the longevity of immunity between SIV-infected and non-
SIV-infected animals. Overall, cell-mediated immune
responses were comparable in both groups although more
variable in the SIV-infected monkeys.
Figure 2 Plasma SIVmac251 viral loads after infection. Sixteen monkeys were classified based on the viral load peak after SIV infection as
follow: (A) high, (B) medium, or (C) low. Viral loads were monitored up to 2 years after SIV infection. 7 months after (represented as a space in
the X axis) eleven surviving monkeys were vaccinated with ML29 and SIV viral loads were reported up to 7 weeks. * denotes monkeys that died
before ML29 vaccination. D) Percentage of variation in SIV viral loads is depicted over the first 3 weeks after ML29 vaccination. Seven of the 8 SIV/
ML29 monkeys experienced a drop in SIV (median 20%) during the first week after vaccination, but those titers returned the following week.
Figure 3 Survival of macaques after SIV-infection and ML29
vaccination. Eleven of 16 rhesus macaques that had been infected
with SIVmac survived to be enrolled in a ML29 vaccination study
(day 393 after SIV infection). Macaques were classified as rapid (>106
SIV RNA mol/ml at setpoint), median (104 – 106 RNA mol/ml), and
slow (<104 RNA mol/ml) AIDS progressors. Eight were vaccinated
with ML29 and three were given LCMV-Armstrong, and all were
monitored for signs of arenavirus disease. Five months after
vaccination, 5 healthy animals remained, having survived 530 days
after SIV infection. The absence of gross signs of arenavirus disease
and the absence of clinical signs in blood and tissues samples
indicated that vaccinated animals were protected from
arenavirus disease.
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PBMC RNA was extracted 1 week after vaccination from
SIV-infected and non-SIV-infected animals. Gene expres-
sion in macaque PBMC was determined by hybridization
to Affymetrix microarrays as described in Methods. Ap-
proximately 100 genes were more than 2-fold differentially
expressed in SIV/ML29-infected animals with respect to
SIV-infection alone. The differentially-expressed genes
were compared with our previously-published RNA pro-
files from LCMV-WE and LCMV-ARM infections in
monkeys [35], that incidentally agree with RNA profiles of
guinea pig infections with virulent and benign virus pairs
[36-38]. We identified 8 genes: OAS1, IFI27, SERPIN B1,
IL-1B, NR4A2, PTGS2 (the gene expressing cyclooxygen-
ase 2), IL-8, and CXCL10 (the gene for cytokine IP-10)
with potential to serve as virulence markers for Lassa-like
arenavirus disease. The expression of these genes in the
ML29-infected monkeys was more similar to their expres-
sion in non-pathogenic LCMV-Armstrong-infected mon-
keys than to their expression in LCMV-WE-infected
monkeys that developed a Lassa-like disease (Figure 6).
Figure 4 Detection of arenavirus in ML29-inoculated macaques. Virus titration by plaque assay revealed that only three animals (SIV/ML-1 •,
SIV/ML-3▴, and SIV/ML-8 ▵) showed low viremia by week 3 after inoculation with ML29. Negative samples were tested by a second round of
amplification (see Methods), showing traces of virus in two animals (ML-3 × and ML-4 ⊙), the remaining animals (▪) tested negative until the end
of the study.
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The two goals of this study were first, to determine
whether ML29 infection can be virulent or persistent
during co-infection with SIV, and second, to determine
whether ML29 is capable of eliciting robust Lassa-specificFigure 5 Percentage of monocytes and NK cells in PBMC after ML29 v
is a significant reduction of the percentage of circulating NK (CD16+) cells
population in four healthy (non-SIV-infected) animals one week after ML29
there is a slight increase in monocytes a week after ML29 vaccination. D) Timmunity in SIV-infected primates. In Lassa fever and in
virulent LCMV-WE infection, viremia greater than 104
pfu/ml plasma is correlated with bad prognosis [39,40].
Here, none of the ML29-vaccinated animals developed
viremia greater than 103 pfu/ml plasma. Nevertheless,accination. A) In the 8 SIV-infected, ML29-vaccinated monkeys there
one week after vaccination. B) Reduction of the NK (CD16+)
vaccination. C) In the 11 SIV-infected, arenavirus-vaccinated monkeys
his increase is also observed in non-SIV-infected control monkeys.
Figure 6 Gene expression of SIV-infected monkeys given the ML29 Lassa vaccine. Column one has the Genbank gene name. Column two
has the fold difference in gene expression between ML29-vaccinated and uninfected (no SIV) monkeys, week 1. Column three has the fold
difference in gene expression between ML29-vaccinated and SIV-infected, week 1. Column four has week one gene expression data from our
previous profiling of monkeys inoculated with virulent and non-virulent strains of LCMV [35]. The blue star indicates indicates potential virulence
markers in primate and guinea pig infections with virulent/mild virus pairs.
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has been seen in uninfected macaques. In our previous
studies with ML29-vaccinated macaques, no infectious
ML29 virus could be detected in urine or plasma but
traces of virus could be detected in lymphoid tissues only
during the first two weeks after vaccination using sensitive
two-step amplification techniques [10]. With ML29-
vaccinated marmosets, only transient viremia was
detected in 3 out of 16 animals by the two-step virus amp-
lification technique, and viral nucleic acids could be
detected in urine, saliva and vaginal swabs from only one
animal [11]. With the SIV-infected monkeys in this study,
the two-step amplification assay detected live ML29 virus
in 3 of 8 ML29-vaccinated monkeys. Of the four SIV/
ML29-monkeys still surviving after 20 weeks, two had
experienced transient ML29 viremia and 2 had not; so the
transient ML29 viremia did not have a measurable impact
on health.
Next we determined whether the arenavirus ML29
established a chronic infection in the SIV-infected mon-
keys. In murine models of LCMV and LASV infection,
immunological defects such as depleted CD4 or CD8+ T
cells often resulted in viral persistence [41,42]. Arena-
virus persistence is unusual in primates but long-term
shedding of LASV has been observed [3], and high IgM
titers against LASV antigens persist for months in Lassa
patients [43]. In the case of SIV-infected monkeys, one
might expect that an ordinarily transient ML29 infection
could persist in the context of immunodeficiency. Mon-
key urine and plasma were monitored weekly, and ML29
virus was not detectable by five weeks after vaccination.
Thus, the SIV-infection did not mediate any detectable
virus persistence.
Classical signs of arenavirus disease include virus
crossing the blood–brain-barrier, high liver enzyme
levels in plasma, and petechiae. Virus was not detectable
in brain tissue of any ML29 animals examined after nec-
ropsy. None of our ML29-vaccinated animals developedhigh levels of AST, ALT, or bilirubin, whereas in Lassa
fever and in lethal LCMV-WE infection, AST greater
than 150 IU/ml plasma indicates poor prognosis
[39,40,44]. Petechiae typical of virulent arenavirus dis-
ease were not observed during daily monitoring of the
ML29-vaccinated animals. Thus, ML29 did not become
virulent in the context of SIV infection.
Non-classical signs of virulence were sought by tran-
scriptome profiling of monkey PBMC-derived RNA. In
our previous studies, extensive transcriptome profiles of
rhesus macaques with virulent and mild arenavirus
infections revealed gene expression that distinguished
arenavirus infection from no infection, and gene expres-
sion that distinguished virulent infection from mild in-
fection [35,45]. Transcriptome profiling of the SIV-
infected rhesus macaques in this study indicated that all
the animals were infected with an arenavirus, and none
of them had gene-expression patterns consistent with
virulent arenavirus infection. Comparison of data
from SIV-infected cohorts with data from SIV/ML29-
infected cohorts revealed differential expression of
specific pathways, including the cyclo-oxygenase/pros-
taglandin (PTGS2) pathway, the Serpin B-related co-
agulation pathway, the nuclear-receptor 4 signaling
pathway, interferon-stimulated genes (ISG) like OAS
and IFI27, and the IL-8/IP-10 chemokines. Studies
described here were consistent with the observation
that SIV/ML29-infected animals did not display signs
of gene expression previously associated with virulent
arenavirus infections.
A second goal of our studies was to determine
whether SIV/ML29-infected animals could elicit im-
mune responses comparable to those seen in animals
given ML29 alone. All but one of the 11 SIV-infected,
arenavirus-infected animals elicited measurable cell-
mediated and humoral immune responses and the levels
were similar to those in the non-SIV-infected cohort.
The one animal with no measurable immunity was a
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ML29 vaccination when he succumbed to AIDS. Cell-
mediated responses were variable in the SIV-infected
cohorts but comparable to the ML29-alone cohorts, and
ML29-specific antibody responses were frequently better
in SIV-infected monkeys than in the non-SIV-infected
monkeys. In a study conducted in LASV-infected cyno-
molgus monkeys [5] LASV-specific IgG responses were
detected 12 days after challenge, with higher titers in
survivors than in fatal cases. This suggests that the
humoral response is induced earlier and more strongly
in nonfatal infections [5]. We failed to observe a correl-
ation between ML29 titers and survival, probably be-
cause survival in our study was due to AIDS progression
and not related to the arenavirus infection.
Several other studies have used non-human primate
AIDS models to explore the safety and efficacy of vac-
cines. In one study, SHIV-infected rhesus macaques
were given a vesicular stomatitis virus-based ebola vac-
cine and all six vaccinees survived a lethal ebola chal-
lenge [17]. In another study SIVmac251-infected rhesus
macaques were vaccinated against smallpox: those with
low CD4 counts failed to elicit neutralizing antibodies
and succumbed to lethal monkeypox challenge, whereas
those with normal CD4 counts elicited neutralizing anti-
body and survived a lethal challenge [18].
In our study all the monkeys maintained normal CD4
counts but exhibited other signs of AIDS including SIV-
viremia, wasting and lymphadenopathy. In fact 5 of the
16 SIV-infected monkeys scheduled for ML29 vaccin-
ation died of AIDS before they could be vaccinated. At-
trition of the remaining 11 animals continued at a rate
expected for death from AIDS alone; all dying macaques
showed signs of AIDS rather than signs of arenavirus
disease.
By the end of our study, 5 monkeys remained healthy
without developing classical or non-classical signs of
virulent arenavirus disease.
Conclusions
SIV-infected macaques given the attenuated Lassa vac-
cine ML29 did not show increased signs of arenavirus
disease or shortened lifespan. A slight increase in ML29
viremia in SIV-infected as compared to non-SIV-infected
macaques was noted. No increased shedding or persist-
ence of ML29 was noted in the SIV-infected hosts.
ML29 elicits cell-mediated and humoral immune




Mopeia/Lassa reassortant virus (clone ML29) was previ-
ously tested as a vaccine against Lassa fever [10,26,27].Vero E6 cells (#CRL-1586, ATCC) were cultured in Dul-
beccos’s modified Eagle’s medium (DMEM, GIBCO-BRL)
supplemented with 10% fetal bovine serum (FBS, GIBCO-
BLR), 1% penicillin-streptomycin, and 2 mML-glutamine.
To produce the ML29 inoculum, Vero cell monolayers
were infected with ML29 master stock at a multiplicity of
infection (MOI) of 0.01 and incubated 1 hour at 37°C in
5% CO2, then washed with PBS and covered in DMEM
2% FBS. Supernatants were collected at 48 and 72 hours
after infection, stored at -70°C, and titrated on Vero cells.
Supernatants usually had about 107 plaque forming units
(pfu)/ml. Stocks of lymphocytic choriomeningitis virus-
Armstrong (LCMV-ARM) and LCMV-WE (described ex-
tensively in [44]) were similarly produced and titrated on
Vero E6 cells and stored at -70°C.
SIVmac251 (originally supplied by Ron Desrosiers)
was amplified on rhesus macaque PBMC and given a
final passage on CEMX174 cells as described [46]. Mon-
keys were infected by inoculating 10 TCID50 per animal
by the saphenous vein.
Whole blood collected in heparin was used to stain for
cell surface and intracellular markers (especially for cell-
mediated immunity assays). Fresh monkey PBMC for
transcriptome analyses were obtained from 10 ml of
heparin blood by Ficoll-hypaque isolation [47] and resus-
pended in RPMI medium 1640 with 10% FBS (Sigma) for
RNA extraction as described below [35]. Residual PBMC
were frozen at -140°C at a concentration of 107 cells/ml.
Upon necropsy, splenocytes were obtained for cell-
mediated immunity assays: fresh tissue pieces were
pressed through mesh, exposed to red cell lysis buffer
5 minutes, then suspended in freezing media and stored at
−140°C at a concentration of 107 cells/ml. Serum samples
and plasma samples were stored at −140°C before being
analyzed for virus or antibody content.
Animals and immunization
Rhesus macaques (Rh) were purchased from the Caribbean
Primate Colony. Experimental protocols were approved by
the Institutional Animal Care and Use Committee at the
University of Maryland School of Medicine. Of 16 mon-
keys inoculated with SIVmac251 as previously described
[19], 5 were dying with symptoms of SIV disease and had
to be euthanized almost a year after SIV infection and be-
fore the onset of the ML29 vaccinations. Of the remaining
11 animals, 8 were inoculated with the ML29 vaccine can-
didate and 3 were inoculated with LCMV-Armstrong,
known to be benign in AIDS monkeys (Salvato MS and
Zapata JC, not shown). Of the 8 ML29-vaccinees, 5 were
inoculated s.c. with 0.5 ml 103 pfu ML29 and 3 were inocu-
lated i..g. with 2 ml 106 pfu ML29. In addition, 5 healthy
control animals were vaccinated s.c. with 0.5 ml of ML29
containing 103 pfu. Blood was collected every week for
flow cytometry, viral loads, antibody detection, clinical
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described [35]. Six weeks after their first vaccination, 6
macaques (ML-1, SIV/ML-1, SIV/ML-2, SIV/ML-6, SIV/
ML-7, SIV/ARM-1) were boosted s.c. with 103 pfu ML29.
Animals were monitored daily for weight loss, rashes and
clinical signs of SIV or arenavirus disease.
For weight loss over 10% of body weight and in
consultation with the veterinary staff, monkeys were
euthanized and total blood and tissues [lung, spleen,
mesenteric lymph nodes (LN), liver, stomach, ileum, kid-
ney, heart, cerebrum, and cerebellum] were collected. A
portion of each tissue was submerged in MEM with 10%
FCS for virus and RNA isolation. The remaining tissue
portions were flash frozen in liquid nitrogen to be used
in virus isolation or fixed in 10% neutral formalin for the
preparation of histological sections. Also, at the end of
the study surviving healthy animals were euthanized and
blood and tissues collected.
Detection of SIV and arenavirus in monkey tissues
SIV viral loads were evaluated from plasma samples using
real-time NASBA to determine the number of RNA cop-
ies per milliliter (Advanced Biosciences Laboratory, Ken-
sington, MD). This technique can detect 100 SIV RNA
copies per ml plasma. Based on SIV-infected animal set
points [48,49], monkeys were considered slow AIDS pro-
gressors (<104 RNA molecules/ml), median progressors
(104 to 106 RNA molecules/ml), and rapid progressors
(>106 RNA molecules/ml). Of the eight SIV-infected ani-
mals inoculated with ML29, two were slow progressors
(SIV/ML-2, SIV/ML-5), 5 were median progressors (SIV/
ML-1, SIV/ML-4, SIV/ML-6, SIV/ML7, and SIV/ML-8)
and one was a rapid progressor (SIV/ML-3). Of the three
monkeys inoculated with the mild LCMV-ARM, one was
a slow progressor (SIV/ARM −2) and two were rapid pro-
gressors (SIV/ARM −1 and SIV/ARM −3).
Arenaviruses were detected by three different meth-
ods: 1) conventional plaque assays that are sensitive to 20
infectious particles in 1 ml solution and were used for
assessments of plasma or tissue viremia for arenaviruses
ML29, LCMV-Armstrong, and LCMV-WE [11]; 2) RT-
PCR that detects 10 viral genomes in 200 μl serum and
was used in all tissues samples (as described in [11]; and
3) a sensitive 2-step amplification assay in which infected
plasma or cells are co-cultivated with Vero cells one week,
then the media is subjected to plaque assay. The 2-step
assay increases the plaque detection up to 1 infectious
particle per ml [10,11].
Flow cytometry to characterize PBMC
Ten ml of whole blood was collected in heparin tubes,
and 100 μl was mixed with each antibody panel (mix-
tures of fluorochrome-conjugated antibodies supplied by
BD Bioscience San Jose, CA). Panel 1 included mouseanti-human CD20-FITC (clone 2H7), CD3-PE (clone
SP34-2), CD4-APC (clone L200), and CD8-PerCP (clone
SK1) to detect B and T lymphocyte populations. Panel 2
included mouse anti-human CD16-FITC (clone 3 G8),
CD56-PE (clone NCAM16.2), CD4-APC (clone L200),
and CD8-PerCP (clone SK1) to detect NK, gamma-delta T
cell (γδT cell), and NKT cell populations. Panel 3 included
CD14-FITC (clone M5E2) and CD4-APC (clone L200),
to detect monocyte and T cell populations. Panel 4
included CD3-PE, and TCR Vgamma9-FITC (clone
IMMU 360, Beckman Coulter). After 30 min, FACS Lys-
ing Solution (BD) was added for red cell lysis and incu-
bated 20 min at room temperature. Cells were washed
twice with PBS and fixed in 2% formaldehyde, then col-
lected in a FACScalibur (BD) and data were analyzed
with FlowJo Software (Tree Star, San Carlos, CA).
Intracellular staining for virus-specific IFNγ responses
Whole heparinized blood (0.5 ml) was stimulated with
<50 μl of ML29 (5 × 105 pfu) or MEM (control) at 37°C,
5% CO2 overnight. 25 μl of 1:10 dilution of monensin
(Golgiplug, BD) was added to each sample 4 hours prior
to staining. Then cells were stained for surface antigens
with anti-CD4-APC (clone L200) and CD8 (clone SK1)
and stained for intracellular IFNγ using monoclonal
antibody 4S.B3 and the Cytofix Cytoperm kit (BD). Sam-
ples were analyzed on a FACSCalibur instrument with
50,000 events in the lymphocyte gate and results were
analyzed using FlowJo software (TreeStar).
IFNγ ELISPOT
PBMC from immunized animals were used in IFNγ ELI-
SPOT (U-CyTech B.V., Ultrecht, The Netherlands) accord-
ing to the manufacturer's recommendations with slight
modifications [10]. Briefly, 2 × 106 cells in 0.5 ml of RPMI-
1640 (Invitrogen) with 5% FBS, 2 mM glutamine, 100
units/ml penicillin, 100 μg/ml streptomycin, and 25 mM
Hepes buffer were stimulated by co-incubation overnight
at 37°C with 2 × 106 pfu of ML29. After stimulation, the
cells were washed, resuspended in the same medium, and
0.3–0.4 × 106 cells/well were added to ELISPOT 96-well
plates pre-coated with mouse anti-monkey IFNγ. The
plates were incubated at 37°C for 5 h, washed, and incu-
bated with gold-conjugated anti-biotin. The spot-forming
cells (SFC) secreting IFNγ were developed with activator
solution and counted (Immunospot 3.2 Analyzer, C.T.L.
Cellular Tech., Ltd.)
ELISA
Anti-LAS-GPC antibodies in serum samples were mea-
sured by IgG ELISA as previously described [10]. Superna-
tants of ML29-infected Vero E6 cells were concentrated in
15 ml Amicon tubes then sonicated using a Misonix-S4000
sonicator (MISONIX, Newtown, CT). This concentrated-
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(pH 9.6), and 100 μl of antigen was adsorbed to the wells
of microtitration plates overnight at 4°C. After washing the
96-well plates 6 times with PBS-Tween (0.05%), two-fold
dilutions (1/50 to 1/400) of plasma were added and incu-
bated for an hour at 37°C. Wells were washed 5 times, and
100 μl of 5,000-times diluted peroxidase-conjugated goat
anti-monkey IgG (A-2054, Sigma) was added and incu-
bated one hr, then washed 6 times, then substrates were
added, incubated for 30 min in the dark, then stopped with
100 μl/well of 1 M phosphoric acid and read at OD450 on a
Wallac 1420 plate-reading spectrophotometer.Gene expression from monkey PBMC cDNA
Total RNA was isolated from fresh PMBC samples,
using the Trizol method (Invitrogen, Carlsbad, CA) fol-
lowed by a cleaning step with RNeasy mini kit (Qiagen,
Valencia, CA). Quality and quantity of all RNA samples
were evaluated on an Agilent 2100 BioAnalyzer 116
(Agilent Technologies, Palo Alto, CA) by looking at 18
and 28 s rRNA peaks and by the RIN (RNA integrity
number). High quality RNA was labeled and hybridized
according to Affymetrix protocols using the human
GeneChip U133 Plus 2.0 array (Affymetrix, Santa Clara,
CA) as described previously [45]. This chip covers the
whole human genome using 54,000 probesets represent-
ing approximately 22,000 genes and has been validated
for use with non-human primates [50-52]. Although
many PBMC-RNA samples were analyzed, the only ones
from sufficiently large groups to yield statistically signifi-
cant data were the SIV-infected samples (n = 8), the SIV/
ML29 s.c. week 1 samples (n = 5) and the SIV/ML29 s.c.
week 2 samples (n = 5). Smaller groups included SIV/
ML29 i.g. weeks 1 and 2, SIV/LCM s.c. weeks 1 and 2,
ML29 i.v. weeks 1 and 2 and the uninfected samples.
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